THU0432 Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled TrialsArthur Kavanaugh, P. J. Mease, Dafna D. Gladman et al.|Annals of the Rheumatic Diseases|2016Cited by 6
AB0943 Sustained improvements with up to 104 weeks of apremilast monotherapy in biologic-naÏve subjects with active psoriatic arthritis: results from a phase 3b, randomised, controlled trialPeter Nash, Jacob Aelion, D. Nguyen et al.|Annals of the Rheumatic Diseases|2018Cited by 0